Search Medical Condition
Please enter condition
Please choose location

Oral Cancer Clinical Trials

A listing of Oral Cancer medical research trials actively recruiting patient volunteers. Search for closest city to find more detailed information on a research study in your area.


Found (85) clinical trials

BAY 1217389 is a potent and highly selective inhibitor of monopolar spindle 1 (MPS1) kinase activity. Human MPS1 is a serine threonine kinase, which functions as a core component of the spindle-assembly checkpoint (SAC), a key surveillance mechanism that monitors the attachment of spindle microtubules to the kinetochores of the ...


This study evaluates the efficacy of TAK-385 for achieving and maintaining testosterone suppression. Evaluates the safety and tolerability of TAK-385, evaluates the efficacy for prostate specific antigen (PSA) lowering. This study also evaluates the quality of life related to androgen deprivation and recovery from androgen deprivation therapy using validated patient-reported ...


MGCD265 belongs to a new class of drugs with anticancer potential, known as tyrosine kinase inhibitors. MGCD265 was shown to slow down the growth of human cancer cells in mice. Clinical studies are being pursued to evaluate the safety of MGCD265 in cancer patients. In this study, MGCD265 is orally ...


A placebo-controlled study comparing an oral drug ODM-201 versus placebo for men with non-metastatic castrate resistant prostate cancer that have a rising PSA and at high risk for developing metastatic disease.


People with oral mucositis and head and neck cancer are asked to participate in a research study being conducted by Montefiore Medical Center.

Phase N/A

Once-daily Oral Seviteronel in Patients With Castration-Resistant Prostate Cancer Progressing on Enzalutamide or Abiraterone.

This is a phase 2 clinical trial of Seviteronel (an oral, potent and lyase-selective CYP17 inhibitor) in men with castration-resistant prostate cancer (CRPC) progressing on enzalutamide or abiraterone. Approximately 197 subjects will be used to assess treatment efficacy. The study will be conducted in two different clinical cohorts separated by ...


Study of Oral PQR309 in Patients With Advanced Solid Tumors

This is a nonrandomized, dose escalation Phase I study designed to evaluate the safety and tolerability of PQR309 in the treatment of selected patients with advanced solid tumors with known activation of AKT/PI3K/mTOR.


Phase 1/2a Study of Oral BAL101553 in Adult Patients With Solid Tumors or Glioblastoma or High-grade Glioma

This is the first study of the oral formulation of BAL101553. BAL101553 will be administered once daily during each day of a 28-day treatment cycle in capsule form to adults with advanced or recurrent solid tumors or recurrent or progressive glioblastoma or high-grade glioma who have failed standard therapy, or ...


A Study of the Effects of GC4419 on Radiation Induced Oral Mucositis in Patients With Head/Neck Cancer

GT-201 is a randomized, double-blind, placebo-controlled, multi-center study conducted in the U.S. to evaluate GC4419 administered IV for the reduction of incidence, duration, and severity of radiation induced oral mucositis in patients receiving cisplatin plus intensity-modulated radiation therapy for post-operative, or definitive treatment of locally advanced, non-metastatic squamous cell carcinoma ...